Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy

Other users also viewed these articles

Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick? Hakan Ozer, Ismail Baloglu, Ali Topkac, Yasin Ozturk, Fethi Yonet, Furkan Daglı, İbrahim Kilinc, Kultigin Turkmen

10.1016/j.nefroe.2023.05.002

Podocyturia in pediatric patients with Fabry disease Miguel Liern, Anabella Collazo, Maylin Valencia, Alejandro Fainboin, Lorena Isse, Cristian Costales-Collaguazo, Federico Ochoa, Graciela Vallejo, Elsa Zotta

10.1016/j.nefroe.2019.03.001

Control of proteinuria with increased doses of agalsidase alfa in a patient with Fabry disease with atypical genotype–phenotype expression Christos Paliouras, Georgios Aperis, Foteini Lamprianou, Giorgos Ntetskas, Konstantinos Roufas, Polichronis Alivanis

10.1016/j.nefroe.2015.09.009